Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background: Prior studies have shown disparities in the uptake of cardioprotective newer glucose-lowering drugs (GLDs), including sodium-glucose cotranwsporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1a). This study aimed to characterize geographic variation in the initiation of newer GLDs and the geographic variation in the disparities in initiating these medications. Methods: Using 2017–2018 claims data from a 15% random nationwide sample of Medicare Part D beneficiaries, we identified individuals diagnosed with type 2 diabetes (T2D), who had ≥1 GLD prescriptions, and did not use SGLT2i or GLP1a in the year prior to the index date,1/1/2018. Patients were followed up for a year. The cohort was spatiotemporally linked to Dartmouth hospital-referral regions (HRRs), with each patient assigned to 1 of 306 HRRs. We performed multivariable Poisson regression to estimate adjusted initiation rates, and multivariable logistic regression to assess racial disparities in each HRR. Results: Among 795,469 individuals with T2D included in the analyses, the mean (SD) age was 73 (10) y, 53.3% were women, 12.2% were non-Hispanic Black, and 7.2% initiated a newer GLD in the follow-up year. In the adjusted model including clinical factors, compared to non-Hispanic White patients, non-Hispanic Black (initiation rate ratio, IRR [95% CI]: 0.66 [0.64–0.68]), American Indian/Alaska Native (0.74 [0.66–0.82]), Hispanic (0.85 [0.82–0.87]), and Asian/Pacific islander (0.94 [0.89–0.98]) patients were less likely to initiate newer GLDs. Significant geographic variation was observed across HRRs, with an initiation rate spanning 2.7%-13.6%. Conclusions: This study uncovered substantial geographic variation and the racial disparities in initiating newer GLDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early evidence in the management of type II diabetes mellitus suggests lower uptake for GLP-1RAs among patients in rural areas compared with urban peers.17”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Sommers, B. D., Blendon, R. J., Orav, E. J., & Epstein, A. M. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.4419 · Cited by 523
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Self-citationJarrín, O. F., Nyandege, A. N., Grafova, I. B., Dong, X., & Lin, H. (2020) · Medical Care · doi:10.1097/mlr.0000000000001216 · Cited by 347
Geographic Distribution of Diagnosed Diabetes in the U.S.
Barker, L. E., Kirtland, K. A., Gregg, E. W., Geiss, L. S., & Thompson, T. J. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2010.12.019 · Cited by 319
Cited by
Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
Spinelli, K. J., Oakes, A. H., Chiu, S., Imboden, M. T., Miller, A. B., Jain, S., & Gluckman, T. J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100100 · Cited by 16
Project ECHO Diabetes Trial Improves Outcomes for Medically Underserved People
Walker, A., Haller, M. J., Addala, A., Filipp, S., Lal, R. A., Gurka, M., Figg, L. E., Hechavarria, M., Zaharieva, D. P., Malden, K. G., et al. (2024) · Diabetes Care · doi:10.2337/dc24-2100 · Cited by 6
Self-citationMoore, J. A., Iheme, N., Rebold, N., Kusi, H., Mere, C., Nwaogwugwu, U., Ettienne, E. B., Chaijamorn, W., & Rungkitwattanakul, D. “. (2025) · Pharmacy · doi:10.3390/pharmacy13020046 · Cited by 12
Klepser, N., Weber, E. S., Li, L., Fleischmann, K. E., Masharani, U. B., Park, M., Max, W. B., Yeboah, J., Hunink, M. G. M., & Ferket, B. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16619 · Cited by 6
Social and Structural Determinants of Cardiovascular Complications of Diabetes
MENSAH, P. A., VALDEZ, K., Gyawali, A., & Snell‐Bergeon, J. K. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01541-7 · Cited by 5
Metadata
- Authors
- Chen, W.-H., Li, Y., Yang, L., Allen, J. M., Shao, H., Donahoo, W. T., Billelo, L., Hu, X., Shenkman, E. A., Bian, J., Smith, S. M., & Guo, J.
- Affiliations
- University of Florida (US)
- University of Pittsburgh (US)
- University of Florida Health (US)
- Emory University (US)
- Rice University (US)
- Corresponding author
- Guo, Jingchuan
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2024-01-29
- Volume
- 19
- Issue
- 1
- Pages
- e0297208
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC10824445
- OpenAlex
- W4391324556
- Cited by
- 17
- References
- 26
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK R01DK133465)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, racial disparities, regional variation, drug initiation, Medicare beneficiaries, cardiovascular benefits, hospital referral regions, non-Hispanic Black patients
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Asian American Native Hawaiian and Pacific Islander, White, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Aged, 80 and over, Black or African American, Diabetes Mellitus, Type 2, Female, Glucose, Hispanic or Latino, Humans, Male, Middle Aged, United States, American Indian or Alaska Native, Racial Groups, Medicare Part D, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes. https://app.cochat.ai/papers/10.1371/journal.pone.0297208
- The paper
- Chen, W.-H., Li, Y., Yang, L., Allen, J. M., Shao, H., Donahoo, W. T., Billelo, L., Hu, X., Shenkman, E. A., Bian, J., Smith, S. M., & Guo, J. (2024). Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes. PLOS ONE. https://doi.org/10.1371/journal.pone.0297208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.